Received: from GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104]) by GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104%5]) with mapi id 15.21.0472.016; Fri, 2 Oct 2026 12:02:28 +0000 Received: from DB1PEPF000509E9.eurprd03.prod.outlook.com (2603:10a6:10:28c:cafe::57) by DU2PR04CA0285.outlook.office365.com (2603:10a6:10:28c::20) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.472.18 via Frontend Transport; Fri, 2 Oct 2026 12:02:34 +0000 Received: from westeu11-emailsignatures-cloud.codetwo.com (20.93.157.195) by DB1PEPF000509E9.mail.protection.outlook.com (10.167.242.59) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.472.14 via Frontend Transport; Fri, 2 Oct 2026 12:02:33 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com (2603:10a6:150:351::5) by WAWPR02MB490611.eurprd02.prod.outlook.com (2603:10a6:1d0:48::24) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.472.18; Fri, 2 Oct 2026 12:02:28 +0000 Received: from GV1PR07CU001.outbound.protection.outlook.com (40.93.214.102) by westeu11-emailsignatures-cloud.codetwo.com with CodeTwo SMTP Server (TLS12) via SMTP; Fri, 02 Oct 2026 12:02:33 +0000 Received: from GV2PR02MB789850.eurprd02.prod.outlook.com (2603:10a6:150:384::15) by AM0PR02MB5011.eurprd02.prod.outlook.com with HTTPS; Fri, 2 Oct 2026 12:02:36 +0000 Received: from DU2PR04CA0285.eurprd04.prod.outlook.com (2603:10a6:10:28c::20) by GV2PR02MB789850.eurprd02.prod.outlook.com (2603:10a6:150:384::15) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.472.18; Fri, 2 Oct 2026 12:02:34 +0000 From: "Kristi Sarap - RA" To: =?utf-8?Q?Taigar_V=C3=A4=C3=A4rtmaa?= References: In-Reply-To: Subject: =?utf-8?Q?Vs:_Delfi_=C3=84rilehe_p=C3=A4ring:_aine_t?= =?utf-8?Q?estimiseks_m=C3=B5eldud_kiirtestide_m?= =?utf-8?Q?=C3=BC=C3=BCk_apteekides?= Date: Fri, 2 Oct 2026 15:02:27 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_00F8_01DD5C80.DD0C19F0" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQE1eK0We/nsrtJSds7/tTQEFzh7PgJqqJAI Authentication-Results: mx.microsoft.com 1; spf=pass (sender IP is 20.93.157.195) smtp.mailfrom=ravimiamet.ee; dkim=none (message not signed) header.d=none;dmarc=pass action=none header.from=ravimiamet.ee; X-MS-Exchange-Organization-ExpirationStartTime: 02 Oct 2026 12:02:33.9411 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: 20658dd3-e5f4-4a99-ecdc-08df207d0b1d X-EOPAttributedMessage: 0 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-PublicTrafficType: Email X-MS-TrafficTypeDiagnostic: GV2PR02MB11921:EE_|WAWPR02MB490611:EE_|DB1PEPF000509E9:EE_|GV2PR02MB789850:EE_|AM0PR02MB5011:EE_ X-MS-Exchange-Organization-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Office365-Filtering-Correlation-Id: 20658dd3-e5f4-4a99-ecdc-08df207d0b1d X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Organization-SCL: 1 X-Microsoft-Antispam: BCL:0;ARA:13230040|366016|82310400026|23010399003|35042699022|39142699007|31052699007|11063799006|18002099003|55112099003|22082099003|8096899003|10067099003|56012099006|41050700001; X-Forefront-Antispam-Report: CIP:20.93.157.195;CTRY:NL;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:westeu11-emailsignatures-cloud.codetwo.com;PTR:westeu11-emailsignatures-cloud.codetwo.com;CAT:NONE;SFS:(13230040)(366016)(82310400026)(23010399003)(35042699022)(39142699007)(31052699007)(11063799006)(18002099003)(55112099003)(22082099003)(8096899003)(10067099003)(56012099006)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 02 Oct 2026 12:02:33.8976 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 20658dd3-e5f4-4a99-ecdc-08df207d0b1d X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-FromEntityHeader: HybridOnPrem X-MS-Exchange-Transport-CrossTenantHeadersStamped: GV2PR02MB789850 X-MS-Exchange-Transport-CrossTenantHeadersStamped: WAWPR02MB490611 X-MS-Exchange-Transport-EndToEndLatency: 00:00:02.6076588 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0472.005 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: en-us x-ms-exchange-organization-originalclientipaddress: 87.119.177.68 x-ms-exchange-organization-originalserveripaddress: 10.167.242.59 received-spf: Pass (protection.outlook.com: domain of ravimiamet.ee designates 20.93.157.195 as permitted sender) receiver=protection.outlook.com; client-ip=20.93.157.195; helo=westeu11-emailsignatures-cloud.codetwo.com; pr=C X-OlkEid: 00000000354180B9476080459B05E1BF834B446F070034AD76187591974DBF6C4F76951C873A01000200000000002495DA25D80D98438130990BFAFE78050000000007C80000113FB8EA8E0D4A4EB163EC78591370BC X-MS-Has-Attach: X-MS-TNEF-Correlator: X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|366016|23010399003|31052699007|39142699007|56012099006|11063799006|8096899003|10067099003|18002099003|22082099003|55112099003|41050700001; X-Microsoft-Antispam-Message-Info-Original: 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 X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV2PR02MB11921.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(366016)(23010399003)(31052699007)(39142699007)(56012099006)(11063799006)(8096899003)(10067099003)(18002099003)(22082099003)(55112099003)(41050700001);DIR:INT; X-Exchange-RoutingPolicyChecked: ZJwCQmMpnrtmGo0yF9+WBhXwhyzTxZretQ+omLZEDVNPMdw2pXEZdjwiLP/MtkFOOJ3uW0PS8BxnSxVDE8HvxJwhU/E9Up67RNE2ixpqjUuoMxLIJfevQe/4aLhPCoAYjkcbpcmB30yeeIvRpbrLHlCm2kbMPYPmeeY6nsXNKoJgxMr831wrqzdWqzgHtcIAaaPoQkN7IU6yXY18Vcz8Fq0VqhQdjDK8UrIxDEP4LxtX8EK4oPqrkfdzWoZ7iMMasxHGnK8OvZArqSsVSbS04aMMZ67QEWLYaeAGJ4Jx9f4FQgn+oAavQzRbASn1FgJVs+DUzXlt/qJJig9M+Zd3nw== X-OrganizationHeadersPreserved: WAWPR02MB490611.eurprd02.prod.outlook.com X-CodeTwo-MessageID: 5284d7ac-bf68-4a66-89d3-5a484c4c5dfe.20261002120233@westeu11-emailsignatures-cloud.codetwo.com X-CodeTwoProcessed: true X-MS-Exchange-Organization-AuthMechanism: 04 X-MS-Exchange-Organization-Recipient-P2-Type: Bcc X-CrossPremisesHeadersPromoted: DB1PEPF000509E9.eurprd03.prod.outlook.com X-CrossPremisesHeadersFiltered: DB1PEPF000509E9.eurprd03.prod.outlook.com X-MS-Exchange-Transport-CrossTenantHeadersStripped: DB1PEPF000509E9.eurprd03.prod.outlook.com X-OriginatorOrg: m1wmgpm3xrpm87txzdfw82by7.smtp.codetwo.online X-MS-Office365-Filtering-Correlation-Id-Prvs: 27fdf104-af7b-417e-c916-08df207d078e X-MS-Exchange-CrossTenant-OriginalAttributedTenantConnectingIp: TenantId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;Ip=[20.93.157.195];Helo=[westeu11-emailsignatures-cloud.codetwo.com] acceptlanguage: et-EE, en-US msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-10-02T12:02:27.331Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; authentication-results-original: mx.microsoft.com 1; dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; x-ms-exchange-messagesentrepresentingtype: 1 This is a multipart message in MIME format. ------=_NextPart_000_00F8_01DD5C80.DD0C19F0 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit _____ Saatja: Taigar Väärtmaa > Saadetud: neljapäev, 1. oktoober 2026 11:29 Adressaat: Kommunikatsioon - RA > Teema: Delfi Ärilehe päring: aine testimiseks mõeldud kiirtestide müük apteekides Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere! Mina olen Taigar Väärtmaa, Delfi Ärilehe juht. Koostan lugu narkootiliste ainete testimiseks mõeldud kiirtestide ja reagentide kättesaadavusest Eestis ning nende valikust apteekides. Jutt ei käi uriini- või süljetestidest, vaid aine enda, pulbri või tableti, kontrollimiseks mõeldud toodetest. Palun Ravimiameti kommentaari järgmistele küsimustele. 1. Millisesse tootekategooriasse kuuluvad aine enda testimiseks mõeldud testiribad ja reagentkomplektid? Kas eri tüüpi testidele kehtivad erinevad nõuded? 2. Kas ja millistel tingimustel võib neid Eesti apteekides müüa? Kas mõni õiguslik piirang takistab nende laiemat pakkumist? 3. Millised nõuded kehtivad nende kvaliteedile, märgistusele ja kasutusjuhendile ning kes kontrollib müüjate väiteid testide täpsuse kohta? 4. Kas Ravimiametile on apteegid või tarnijad nende toodete müügi kohta päringuid esitanud? Milliseid takistusi on välja toodud? 5. Kas ravimiamet näeb probleemi selles, et testribade kättesaadavus Eestis on pealtnäha kehv. Neid müüvad mõned nišši veebipoed, aga mitte apteegid. Kui mõni küsimus kuulub teise asutuse pädevusse, palun võimalusel viidata õigele kontaktile. Lugu ilmub laupäeval, 3. oktoobril. Seetõttu palun vastuseid reedeks, 2. oktoobriks kell 15.00. Kui selleks ajaks vastamine pole võimalik, palun sellest teada anda. Lugupidamisega Taigar Väärtmaa Delfi Ärileht, Ärilehe juht Delfi Meedia AS | Narva mnt 13, Tallinn 10151 | Mob: +3​72 54470749 ------=_NextPart_000_00F8_01DD5C80.DD0C19F0 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable

 

Saatja: Taigar V=C3=A4=C3=A4rtmaa = <taigar.vaartmaa@arileht.ee= >
Saadetud: neljap=C3=A4ev, 1. oktoober 2026 = 11:29
Adressaat: Kommunikatsioon - RA <press@ravimiamet.ee>
Tee= ma: Delfi =C3=84rilehe p=C3=A4ring: aine testimiseks m=C3=B5eldud = kiirtestide m=C3=BC=C3=BCk apteekides =

 

T=C3=A4helepanu! Tegemist on v=C3=A4lisv=C3=B5rgust = saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte = avada.

Tere!

Mina olen Taigar V=C3=A4=C3=A4rtmaa, Delfi = =C3=84rilehe juht. Koostan lugu narkootiliste ainete testimiseks = m=C3=B5eldud kiirtestide ja reagentide k=C3=A4ttesaadavusest Eestis ning = nende valikust apteekides.

Jutt ei k=C3=A4i uriini- v=C3=B5i = s=C3=BCljetestidest, vaid aine enda, pulbri v=C3=B5i tableti, = kontrollimiseks m=C3=B5eldud toodetest.

Palun Ravimiameti kommentaari j=C3=A4rgmistele = k=C3=BCsimustele.

  1. Millisesse = tootekategooriasse kuuluvad aine enda testimiseks m=C3=B5eldud = testiribad ja reagentkomplektid? Kas eri t=C3=BC=C3=BCpi testidele = kehtivad erinevad n=C3=B5uded?
  1. Kas ja millistel = tingimustel v=C3=B5ib neid Eesti apteekides m=C3=BC=C3=BCa? Kas = m=C3=B5ni =C3=B5iguslik piirang takistab nende laiemat = pakkumist?
  1. Millised n=C3=B5uded = kehtivad nende kvaliteedile, m=C3=A4rgistusele ja kasutusjuhendile ning = kes kontrollib m=C3=BC=C3=BCjate v=C3=A4iteid testide t=C3=A4psuse = kohta?
  1. Kas Ravimiametile on = apteegid v=C3=B5i tarnijad nende toodete m=C3=BC=C3=BCgi kohta = p=C3=A4ringuid esitanud? Milliseid takistusi on v=C3=A4lja = toodud?
  1. Kas ravimiamet = n=C3=A4eb probleemi selles, et testribade k=C3=A4ttesaadavus Eestis on = pealtn=C3=A4ha kehv. Neid m=C3=BC=C3=BCvad m=C3=B5ned ni=C5=A1=C5=A1i = veebipoed, aga mitte apteegid.

Kui m=C3=B5ni k=C3=BCsimus kuulub teise asutuse = p=C3=A4devusse, palun v=C3=B5imalusel viidata =C3=B5igele = kontaktile.

Lugu ilmub laup=C3=A4eval, 3. oktoobril. = Seet=C3=B5ttu palun vastuseid reedeks, 2. oktoobriks kell = 15.00. Kui selleks ajaks vastamine pole v=C3=B5imalik, = palun sellest teada anda.

Lugupidamisega

 

Taigar V=C3=A4=C3=A4rtmaa

Delfi =C3=84rileht, =C3=84rilehe = juht

 

Delfi  Meedia AS | Narva mnt 13, Tallinn 10151 | Mob: +3=E2=80=8B72 = 54470749

 

------=_NextPart_000_00F8_01DD5C80.DD0C19F0--